UBS Group
KERX

UBS Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

UBS Group’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-300
Closed -$2K – 8515
2015
Q4 		$2K Sell
300
-97,900
-100% -$465K ﹤0.01% 8072
2015
Q3 		$346K Buy
98,200
+97,900
+32,633% +$656K ﹤0.01% 4196
2015
Q2 		$3K Hold
300
– – ﹤0.01% 8115
2015
Q1 		$4K Sell
300
-3,200
-91% -$41.1K ﹤0.01% 8259
2014
Q4 		$50K Buy
+3,500
New +$54.2K ﹤0.01% 6490

UBS Group's KERX Position: Q4 2018 in Review

UBS Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 51,534 shares — an estimated $175K sold.

UBS Group first reported a position in KERX in Q4 2014 and held it in 16 quarters. The position peaked at $4.28M in Q1 2015. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • UBS Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • UBS Group sold 51,534 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $175K.
  • UBS Group first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 16 quarters.
  • UBS Group's Keryx Biopharmaceuticals Inc position peaked at $4.28M in Q1 2015.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on UBS Group's 13F filing for Q4 2018, filed 14 Feb 2019.